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Trends in epidemiology of Hepatitis B and C Infections  
in Ilam Province: National Notifiable Diseases  
Surveillance System data 
 
Abstract 
Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections are the main 
causes of severe liver failure worldwide. This study was conducted to evaluate the 
incidence rate and trend of these infections over six successive years from 2008 to 2013 in 
Ilam Province, western Iran. 
Methods: We studied the registered data of HBV and HCV based on the National 
Notifiable Diseases Surveillance System in Ilam Province from 2008 to 2013. Incidence 
rate per 100,000 populations was estimated for HBV and HCV infections through location, 
years and age groups of patients. 
Results: The overall incidence rate per 100,000 populations from 2008 to 2013 for HBV 
infection was 9.57, 5.83, 16.26, 12.44, 21.89 and 13.93, respectively. The corresponding 
values for HCV infection were 0.55, 0.72, 1.44, 2.69, 1.24 and 1.93, respectively and these 
trends for both the HBV and HCV infections were increasing. The major distribution of 
HBV and HCV infections was 25-44 years of age. Both HBV and HCV infections were 
more common in males, urban areas and married patients. Forty-one percent of cases were 
carriers and history of surgery was the common risk factor. 
Conclusions: Our results showed that HBV and HCV are prevalent in the middle-age 
group. Despite effective vaccination against hepatitis B, optimized blood donor screening 
and better sterilization procedures for blood products, trend of HBV and HCV in Ilam are 
increasing. Further studies should address the role other risk factors in the trend of HBV 
and HCV. 
Keywords: Hepatitis B; Hepatitis C; Incidence, Trend, Iran 
Citation: 
Khazaei S, Karami M, Ayubi E, et al. Trends in epidemiology of Hepatitis B and C Infections in 
Ilam Province: National Notifiable Diseases Surveillance System data. Caspian J Intern Med 2018; 
9(1):16-21. 
 
 
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are the main causes of severe 
liver failure, including hepatocellular carcinoma (HCC) and cirrhosis (1). Approximately 
80% of HCC cases are attributed to chronic HBV or HCV infections (2). It is estimated 
that nearly 350 million people worldwide have chronic HBV. This value for chronic HCV 
is 170 million (3). HBV is highly contagious and transmitted mainly via blood transfusion, 
unsafe injection practices, sexual contact and mother to child transmission (4). HCV 
transition way is similar to HBV and it is estimated that about 3% of the populations in the 
world are carriers of HCV, with 3 to 4 million new infections per year (5). Unlike HCV, 
HBV vaccine has been available since 1982, and has a high effect in the prevention of 
HBV transmission (4). Due to asymptomatic and latent nature of these diseases prior to 
clinical stage, calculating prevalence rates across the world is difficult (6). The prevalence 
of HBV infection is very diverse all over the world ranging from highly endemic areas (> 
8% infection rate) in South-East Asia and the sub-Saharan regions, intermediate (2-8%) in 
Mediterranean countries and Japan to low endemic areas (< 2%) in the United States and 
Western Europe (7).   
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WHO estimations show that the Eastern Mediterranean 
region of WHO has the largest reservoir of HCV globally 
with the prevalence rate of 11% to 14% (3). The result of the 
systematic review study showed that in Iran, the prevalence 
of the HBV infection was estimated 2.14% and ranged from 
1.3% in Kermanshah, East Azarbaijan and Isfahan to 6.3% in 
Golestan province (8), In another study,  history of surgery 
and imprisonment were the main risk factors for the HBV 
infection (9). The prevalence of HBV infection in general 
population in Iran is less than 1%, lower than in most of the 
regional countries (10). 
The evaluation of the prevalence and distribution of HBV 
and HCV is important for the planning of prevention 
programs and the provision of necessary medical equipment 
particularly in the case of HBV for the development of 
vaccination programs (11). Considering the national 
vaccination programs for hepatitis B, optimized blood donor 
screening and better sterilization procedures for blood 
products in Iran, we expect to have a decreasing trend in the 
incidence rate of diseases in Ilam. Accordingly, this study 
aimed to address the epidemiological profile of HBV and 
HCV in Ilam province from 2008 to 2013.  
 
 
Methods 
We studied the registered data of the HBV and HCV 
reported cases to the provincial level of National Notifiable 
Diseases Surveillance System in Ilam Province from 2008 to 
2013. Ilam is located in the west of the country bordering 
Iraq. The population of the province is approximately 
600,000 people (2015 estimate). According to National 
guideline hepatitis management, notification of HBV and 
HCV infections in Iran is mandatory (12). Therefore, all 
public and private laboratories, blood transfusion 
organization, hospitals and health centers should report all 
positive test results of serologic markers of HBV and HCV 
infections to the affiliated district health center monthly. All 
patients with positive serologic markers for HBsAg or anti-
HCV were considered as suspected positive cases of HBV or 
HCV infections, respectively and were included in the study. 
To reach the homogenous and generalizable data, those 
patients who lived in other provinces were excluded from the 
study. Moreover, to consider only new cases, cases with 
previous history of disease were excluded and only incident 
cases in this period enrolled in the study. Then, complete 
examination forms for identifying detected cases was done 
by the health staff. This form includes data on demographic 
characteristics of the patients (age, gender, marital status, 
and residence), history of high risk behavior, cause of 
examination and disease situation in other family members 
with similar situation. 
Incidence rate per 100,000 populations estimated for 
HBV/ HCV infections was disaggregated by location and 
age group of patients. The average annual rate of 
reduction/increase (AARR/I) was calculated using a 
regression analysis to quantify the rate of change of the 
incidence rate from 2008 to 2013. To this end, the incidence 
rate of HBV and HCV infection and the year were 
considered as the dependent and independent variables, 
respectively. Then, using the coefficient (B) obtained the 
AARR was calculated with the following formula (13): 
AARR= 1-EXP(B). Sign of coefficient (B) was accounted 
for direction of trend. In fact, change in incidence is assumed 
to take an exponential function. For any given year t, if the 
incidence is known to be Yt, and the annual rate of reduction 
or increase is constantly b%, then the incidence of the next 
year, denoted as Yt+1, can be calculated as: Yt+1 = Yt*(1-
b%) 
Chi square test was used to compare some infection types 
(HBV, HCV, HBV & HCV) according to the mentioned 
variables. Statistical analysis was performed using the 
Microsoft Excel program and the Stata software, Version 12 
(Stata Corp, College Station, TX, USA). 
 
 
Results 
During the study period, number of 568 patients (514 
subjects with HBV infection, 48 subjects with HCV 
infection and 6 cases of HBV & HCV co-infection) were 
reported to the provincial level of National Notifiable 
Diseases Surveillance System in Ilam. Their mean age was 
39.12±15.18 years (range 1–87 years). 
The overall incidence rate pre 100,000 populations from 
2008 to 2013 for HBV infection was 9.57, 5.83, 16.26, 
12.44, 21.89 and 13.93, respectively. The corresponding 
values for HCV infection were 0.55, 0.72, 1.44, 2.69, 1.24 
and 1.93, respectively. The incidence rates of HBV and HCV 
according to their location and years of study are shown in 
figure 1. Finding shows that the overall incidence rate for 
both HBV (Urban areas: β=0.19, P=0.11, rural areas: 
β=0.17, P=0.11) and HCV (urban areas: β= 0.29, P=0.11, 
rural areas: β=0.11, P=0.15) is increasing.  
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Figure 1: The incidence rate of hepatitis B and hepatitis 
C virus by location and year 
 
The absolute frequency distribution of HBV and HCV 
infections by age and their relevant incidence rates are 
shown in figure 2. Majority of HBV and HCV infections 
were observed among individuals who have 25-44 years old. 
Also, the line curves indicate that the incidence rates of both 
hepatitis B and hepatitis C are the highest in this age group. 
High incidence rates of hepatitis B above 65 years old 
subjects are remarkable. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The frequency and incidence rate of hepatitis B 
and C infection by age group 
 
Figure 3 shows the occupational status of subjects under 
study. Both hepatitis B and C are more common among 
women housekeepers and self-employed subjects. 
 
 
   
 
 
 
 
 
 
 
 
Figure 3. Occupational status of hepatitis B and C 
infected patients 
 
Demographic characteristics of hepatitis B, C and HBV 
and HCV co-infected patients are shown in Table 1. About 
52% (299) cases of the study participants were males, 464 
(81.69%) of them were married and 397 (69.89%) lived in 
urban areas. In 20.77, 17.61, 15.49 and 11.09 percent of 
subjects, the causes of examination were history pregnancy, 
volunteer, clinical symptoms and history of high risk 
behavior. 41.02% of cases were carriers and 27.29% of them 
were in chronic stage. There was a significant association 
between infection type and gender, marital status and cause 
of examination and (p<0.05). Of the 568 cases reported, 274 
subjects mentioned history of risk factor related to HBV and 
HCV. Nonparticipants were similar to participants with 
respect to age, sex and location. Among subjects who 
mentioned history of risk factor related to these diseases, 
surgery was a commonly recognized risk factor for infection 
identified 18.7% of participants. Infection in other family 
members (16.3%) and blood transfusion (7.57%) were the 
other predominant risk factors for infection. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. History of risk factors of HBV and HCV 
infections among patients under study 
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Table 1. Baseline characteristics of hepatitis B, C and HBV and HCV co-infected patients 
Variable 
Total 
(N=568) 
HBV 
(N=514) 
HCV 
(N=48) 
pvalue
* HBV & HCV 
(N=6) 
Gender 
Male 299 (52.64) 259 (86.62) 37 (12.37) 
<0.001 
3 (1.00) 
Female 269 (47.36) 255 (94.80) 11 (4.09) 3 (1.12) 
Marital 
status 
Married 464 (81.69) 430 (92.67) 31 (6.68) 
0.003 
3 (4.90) 
Single 93 (16.37) 75 (80.65) 16 (7.90) 2 (2.15) 
Divorce 11 (1.94) 9 (81.82) 1 (9.09) 1(9.09) 
Location 
Rural 171 (30.11) 162 (94.74) 8 (4.68) 
0.032 
1 (0.58) 
Urban 397 (69.89) 352 (88.66) 40 (10.08) 5 (1.26) 
Cause of examination 
Clinical symptoms 88 (15.49) 85 (96.59) 2 (2.27) 
<0.001 
1 (1.14) 
High risk behavior 63 (11.09) 41 (65.08) 19 (30.16) 3 (4.76) 
Pregnancy 118 (20.77) 117 (99.15) 0 (0.00) 1 (0.085) 
Volunteer 100 (17.61) 90 (90.00) 9 (9.00) 1 (1.00) 
Other 199 (35.04) 181 (90.95) 18 (9.05) 0 (0.00) 
* P values were obtained from HBV and HCV patient comparison based on their baseline characteristics. 
 
Discussion 
HBV is considered as a major public health problem in 
many countries affecting a large number of populations 
worldwide. Iran is located in the Middle East, known as an 
area with an intermediate prevalence of HBV infection (14). 
In Iran, the mass vaccination program for HBV started in 
1993 (15). In the present study, both the information of the 
568 HBV/HCV patients in Ilam province for six year 
surveillance (2008 to 2013) was used. This study indicated 
that the overall incidence rate of HBV and HCV infection is 
increasing and the major distribution of HBV and HCV is in 
25-44 years group. 90.42% of subjects were HBsAg positive 
and these infections were more common among males, 
married patients and those in urban areas. 41.02% of cases 
were carriers and history of surgery was the common risk 
factor among the subjects. 
Unlike the results of this study, findings of the similar 
study in Hamedan showed a downward trend of HBV and 
unsteady trend of HCV infection (16). One reason of this 
contradiction may be due to the differences in the years of 
two studies. In return, the results of the another study in Iran 
was consistent with our results (17). Increasing trend of 
HCV infection can justify an increase in the number of 
intravenous drug users (IDUs). In fact, HCV infection is an 
emerging disease in our country due to IDUs (10). In Latin 
America in most parts the prevalence has remained in a flat 
period or increasing, as injection drug use is not common in 
these countries, therefore other risk factors play a major role 
in new infections (18). In some studies, increase in the total 
number of donations was associated with the increasing  
 
incidence of infection in those years (19). The increase in 
blood donation, cesarean delivery and surgery in a year can 
be associated with increased incidence. It is necessary to 
note that this increase in trends was not statistically 
significant. In this study, the major distribution of HBV and 
HCV was in 25-44 years group. The low incidence rate of 
HBV infection in less than 25 years of age is attributed to 
mass vaccination against HBV infection began in 1993 
among neonates and immunity as well (14). The low 
incidence rate of HCV in this age group could be due to the 
usually initiation of drug injection that occurred among 
injection drug users (20, 21). Although few subjects have 
mentioned the history of drug use as a risk factor, it should 
be noted that in this study about 57% of them refused to 
answer this question. Given that injecting drug use is an 
illegal and stigma impacted behavior, therefore most of them 
were reluctant to answer this question, likewise the sex 
workers (22). Health planning should note the high incidence 
rate of HBV and HCV infections in the age group over 65 
years in spite of its low frequency. 
More than 16% of participants had positive HBV or HCV 
case in their household. Some studies have shown a 
relatively higher prevalence in the household members with 
the HBV or HCV positive patients (14, 23). One reason may 
be due to the fact that they exist in the same community with 
the same risk factors as their patient in the family. Another 
reason may be due to pharmaceutical injection for patients at 
home or exposure to the patient’s contaminated needles or 
syringes. In terms of transmission via blood transfusion due 
to precise would be donor screening process and the 
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elimination of high-risk donors after 1996 in Iran, this way 
of transmission would be negligible (24). Fortunately, 
immunization of high-risk groups, such as health care 
workers, other family members of positive case and blood 
product recipients against HBV infection, is in process 
according to the recommendation of national vaccination 
program (15). There was no tremendous difference in the 
incidence of the disease between males and females. This 
might be related to the fact that cesarean surgery belongs to 
women, furthermore, because of the tests done during 
pregnancy, women attend more screening than men. In 
return, needle sharing among intravenous drug abusers and 
imprisonment are more common in males (21). The result of 
the population-based study in three provinces in Iran showed 
that HCV is more common among males but for HBV, there 
was no significant preponderance regarding sex (17). Some 
studies indicated higher prevalence of HBsAg among males 
(25, 26). Regarding residency, in this study, HBV / HCV 
infection was higher in urban areas. One reason for this 
difference is due to the rural and urban population 
composition difference in Ilam province (urban/ rural ratio: 
1.84). In addition, HBV and HCV infections are more 
common in married participants. One reason is that, most 
married people have not been included in the national 
vaccination programs and are not protected against the 
infection; another cause is due to sexual contact between 
couples. This result is consistent with the findings of other 
studies in the east of Iran (27).  
The first limitation of this study concerns the collected 
data based on passive surveillance system, therefore 
underreporting and lack of completeness are inevitable in 
this study (28). The second limitation is that, HBV and HCV 
infections usually affect chronic patients without symptoms 
and patients usually accidentally diagnosed during blood 
donation, during pregnancy screening or due to a positive 
case in other family members, hence the results strongly 
suggest underestimation (29, 30). Third, confirmatory tests 
have not been used for definitive diagnosis of subjects 
including recheck of HBsAg for chronic HBV infection 
diagnosis and more specific tests to confirm HCV infection, 
thus some reported cases may be false positive. And fourth is 
owing to self-reported answer to some questions, 
consequently, some results are prone to information bias. 
Despite the limitations of passive surveillance systems like 
low sensitivity, alongside the low cost and easy to carry out, 
these systems are useful in monitoring trends over time and 
providing critical information to monitor  community health 
(31), which is consistent with the objectives of our study. 
In conclusion, our results showed that HBV/HCV 
infections are concentrated in the middle age group. Despite 
vaccine effectiveness against hepatitis B, optimized blood 
donor screening and better sterilization procedures for trends 
in blood products of HBV and HCV infections in this study 
are increasing, as a result, the other risk factors may play a 
major role in new infections, So, there is a need to do more 
studies in this regard. Immunization against HBV infection 
for high-risk groups, such as health care workers, other 
family members of positive cases and blood product 
recipients who have no history of vaccination, should be 
done more seriously. 
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